Aromatase Inhibitors (AIs) or hormone-therapy drugs reduce the risk of breast cancer recurrence, but they often lead to bone loss or severe joint pain, known as arthralgia.
Hence, many survivors - nearly 40 per cent of them, according to one study - stop taking AIs long before their customary five-year treatment period expires.
"When women quit taking AIs, they increase the chances of their breast cancer re-occurring," said Gwendolyn Thomas from the Syracuse University in the US.
For the study, participants did two sessions of weight training and 150 minutes of moderate aerobic activity, such as brisk walking or jogging, every week for a year.
The researchers then monitored the participant's body composition, including their body mass index, per cent body fat, lean body mass and bone mineral density.
"We noticed a drop in per cent body fat and body mass index, as well as a significant increase in their lean body mass," said Thomas.
It is well documented that breast cancer is the most common cancer diagnosis among American women. Moreover, about 65 per cent of breast cancer survivors are overweight or obese.
Since most breast cancers are hormone receptor-positive - they use estrogen or progesterone to grow and spread - survivors often rely on hormone therapy, such as AIs, to keep the disease from returning.
AI treatment, however, can be a double-edged sword because of the aforementioned effects that are not connected to age-related decline.
The study appears in Obesity Journal.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
